Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Ependymoma × Etoposide × Clear all

Phase

Status

Completed 6 Active not recruiting 3 Recruiting 2 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 17 Leukemia, Myeloid, Acute 17 Lymphoma 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Lymphoma, Non-Hodgkin 15 Lymphoma, Large B-Cell, Diffuse 15 Lung Neoplasms 12 Leukemia 12 Burkitt Lymphoma 11 Carcinoma, Non-Small-Cell Lung 10 Recurrence 8 Multiple Myeloma 8 Lymphoma, Follicular 8 Leukemia, Lymphocytic, Chronic, B-Cell 7 Hodgkin Disease 7 Sarcoma 5 Myelodysplastic Syndromes 5 Congenital Abnormalities 5 Sezary Syndrome 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Ovarian Neoplasms 4 Neuroblastoma 4 Neoplasms, Plasma Cell 4 Mycosis Fungoides 4 Lymphoma, T-Cell, Cutaneous 4 Lymphoma, Mantle-Cell 4 Lymphoma, Large-Cell, Immunoblastic 4 Lymphoma, B-Cell, Marginal Zone 4 Lymphoma, B-Cell 4 Leukemia, Hairy Cell 4

Interventions

Temozolomide 4 Radiotherapy 2 Gadolinium DTPA 2 Filgrastim 2 Erlotinib Hydrochloride 2 vitespin 1 sargramostim 1 picropodophyllin 1 imetelstat 1 gadobutrol 1 gadobenic acid 1 bempegaldesleukin 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Yoga 1 Transurethral Resection of Bladder 1 Thiotepa 1 Surgical Procedures, Operative 1 Ritonavir 1 Radiation 1 Peripheral Blood Stem Cell Transplantation 1 Perfusion Magnetic Resonance Imaging 1 O(6)-benzylguanine 1 Nivolumab 1 Methylphenidate 1 Melphalan 1 Lopinavir 1 Immunohistochemistry 1 Imiquimod 1 Granulocyte Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated

25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡